siRNA News and Research

RSS

Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA molecules, 20-25 nucleotides in length, that play a variety of roles in biology. Most notably, siRNA is involved in the RNA interference (RNAi) pathway, where it interferes with the expression of a specific gene. In addition to their role in the RNAi pathway, siRNAs also act in RNAi-related pathways, e.g., as an antiviral mechanism or in shaping the chromatin structure of a genome; the complexity of these pathways is only now being elucidated.

New book reveals promising nanomaterials for therapeutic drug delivery

'Nanomaterials: Evolution and Advancement Towards Therapeutic Drug Delivery' gives the present status and future perspective of Polymeric nanoparticles, Liposomes, Carbon Nanotubes, Magnetic Nanoparticles, Silica Based nanomaterial, Hydrogels, Metallic Nanoparticles, Cyclodextrins, Poly (Lactide-Co-Glycolide) and its Copolymers.

25 Jun 2021

New approach could revolutionize treatment, prevention of Parkinson’s disease

Researchers from Brain Research Institute, Niigata University, Japan may have unraveled a new approach that could revolutionize the treatment, prevention, and possibly reversal of the damages that could lead to Parkinson's Disease (PD).

11 Jun 2021

Synthetic microRNA can serve as a novel therapeutic agent for treating human cancer

Oncotarget published "Multi-modal effects of 1B3, a novel synthetic miR-193a-3p mimic, support strong potential for therapeutic intervention in oncology" which reported that the authors comprehensively investigated miRNA-193a-3p's mode of action in a panel of human cancer cell lines, with a variety of genetic backgrounds, using 1B3, a synthetic microRNA mimic

2 Jun 2021

Scientists develop experimental direct-acting antiviral therapy to treat COVID-19

An international team of scientists from the Menzies Health Institute Queensland (MHIQ) at Griffith University and from City of Hope, a research and treatment center for cancer, diabetes and other life-threatening diseases in the U.S., have developed an experimental direct-acting antiviral therapy to treat COVID-19.

18 May 2021

ErbB inhibitor lapatinib exhibits potent anti-SARS-CoV-2 activity

A team of scientists from the USA and Belgium has recently revealed that the ErbB family of receptor tyrosine kinases play a vital role in regulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lifecycle in host cells and that inhibition of these receptors can protect against SARS-CoV-2-induced acute and chronic lung injuries and inflammation.

18 May 2021

A promising drug delivery system for therapeutics that shut down harmful genes

Viruses attack the body by sending their genetic code -- DNA and RNA -- into cells and multiplying. A promising class of therapeutics that uses synthetic nucleic acids to target and shut down specific, harmful genes and prevent viruses from spreading is gaining steam.

18 May 2021

Nanotechnology and COVID-19 diagnosis and treatment

The development of nano-biosensors and nanoparticle-based vaccines and medicines has opened a new path toward better management of the coronavirus disease 2019 (COVID-19) pandemic. In a recently published article in the journal ACS Biomaterials Science & Engineering, scientists have reviewed recent advancements in nanotechnology-based diagnostic and therapeutic interventions against human coronaviruses.

17 May 2021

Using ultrasound and RNA-loaded nanoparticles to deliver potent medicine to brain tumors

RNA-based drugs have the potential to change the standard of care for many diseases, making personalized medicine a reality. This rapidly expanding class of therapeutics are cost-effective, fairly easy to manufacture, and able to go where no drug has gone before, reaching previously undruggable pathways.

7 May 2021

Interfering RNA nanoparticles could be a potential COVID-19 therapy

Study shows lipid nanoparticle-based siRNA is potent in suppressing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent of coronavirus disease 2019 (COVID-19) – in cells as well as in mice models.

21 Apr 2021

Topical drug regenerates, restores function of erectile nerves damaged by radical prostatectomy

Researchers at Albert Einstein College of Medicine have developed a topical drug that regenerates and restores the function of erectile nerves damaged by radical prostatectomy, the most common treatment for localized prostate cancer.

19 Apr 2021

Changes in OASI gene expression increases risk of Alzheimer's and severe COVID-19 infection

Previous research identified the interferon-responsive OAS1 gene as a risk gene for Alzheimer's disease. OAS1 is an enzyme that binds to double-stranded RNA and induces the conformation to create oligoadenylates. They also activate RNase L to break down RNA.

23 Mar 2021

Scientists develop RNA-based therapeutic strategy for Charcot-Marie Tooth disease

Charcot-Marie Tooth disease is the most common hereditary neurological disease in the world. It affects the peripheral nerves and causes progressive paralysis of the legs and hands.

9 Mar 2021

Study identifies potential therapeutic target for non-alcoholic fatty liver disease

An international team of researchers has identified the CNNM4 protein as a key regulator of magnesium in the liver and potential therapeutic target for non-alcoholic fatty liver disease, according to a study published in the Journal of Hepatology.

4 Mar 2021

mRNA Therapeutics – Analytical and Bioanalytical Characterization

NewsMed interviews Anette Bak from AstraZeneca about her research on developments in mRNA therapeutics that she will present at Pittcon 2021.

From Pittcon 23 Feb 2021

Researchers develop ultra-small nanomedicines to target intractable cancers

Ultra-small nanomedicines of approximately 18 nm were fabricated by dynamic ion-pairing between Y-shaped block copolymers and nucleic acid drugs, such as siRNA and antisense drugs.

19 Jan 2021

Researchers use aerosolized molecules to shut down proteins generated by coronavirus

Researchers at Georgetown University Medical Center have successfully used molecules comprised of small strands of RNA to shut down the production of destructive proteins generated by the COVID-19 virus.

16 Nov 2020

Novel super-activating macrophage receptor could explain hyper-inflammation in severe COVID-19

Immunity is a curious thing. While essential in protecting the body against invading pathogens and foreign antigens, it can also turn against the body and trigger destructive immunological processes. A new study published on the preprint server bioRxiv* in November 2020 reports on the role played by hyperactive macrophages in a range of acute and chronic hyper-inflammatory conditions.

10 Nov 2020

Antiviral inhibitor DDX42 shows broad activity against Chikungunya, HIV and SARS-CoV-2

By exploiting type 1 interferon's ability to foster an antagonistic cellular environment for viral replication, a research group from France pinpointed DEAD-box RNA helicase DDX42 as an intrinsic inhibitor of HIV, but also other pathogenic viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Chikungunya virus.

29 Oct 2020

Researchers find a new therapeutic approach to combat leukemia

Leukemia frequently originates from the so-called leukemic stem cell, which resides in a tumor promoting and protecting niche within the bone marrow. Scientists from the Max Planck Institute of Biochemistry in Martinsried, Germany, have found a new way to make these cells vulnerable by specifically dislodging these cells from their niches.

23 Oct 2020

Design of an mRNA SARS-CoV-2 vaccine encapsulated in lipid nanoparticles

Now, a new study presented on the preprint server bioRxiv in October 2020 describes the efficient design of an mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), based on the use of the viral receptor-binding domain (RBD) mRNA encapsulated in lipid nanoparticles (LNP).

19 Oct 2020

siRNA News and Research

New book reveals promising nanomaterials for therapeutic drug delivery

New approach could revolutionize treatment, prevention of Parkinson’s disease

Synthetic microRNA can serve as a novel therapeutic agent for treating human cancer

Scientists develop experimental direct-acting antiviral therapy to treat COVID-19

ErbB inhibitor lapatinib exhibits potent anti-SARS-CoV-2 activity

A promising drug delivery system for therapeutics that shut down harmful genes

Nanotechnology and COVID-19 diagnosis and treatment

Using ultrasound and RNA-loaded nanoparticles to deliver potent medicine to brain tumors

Interfering RNA nanoparticles could be a potential COVID-19 therapy

Topical drug regenerates, restores function of erectile nerves damaged by radical prostatectomy

Changes in OASI gene expression increases risk of Alzheimer's and severe COVID-19 infection

Scientists develop RNA-based therapeutic strategy for Charcot-Marie Tooth disease

Study identifies potential therapeutic target for non-alcoholic fatty liver disease

mRNA Therapeutics – Analytical and Bioanalytical Characterization

Researchers develop ultra-small nanomedicines to target intractable cancers

Researchers use aerosolized molecules to shut down proteins generated by coronavirus

Novel super-activating macrophage receptor could explain hyper-inflammation in severe COVID-19

Antiviral inhibitor DDX42 shows broad activity against Chikungunya, HIV and SARS-CoV-2

Researchers find a new therapeutic approach to combat leukemia

Design of an mRNA SARS-CoV-2 vaccine encapsulated in lipid nanoparticles

World Brain Day 2021: An interview with Professor Alan Thompson

Preventing lethal blood clots

Curbing COVID-19 through border controls and restricted entry

Latest News